Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products

Kenneth Cornetta, Lisa Duffy, Cameron J. Turtle, Michael Jensen, Stephen Forman, Gwendolyn Binder-Scholl, Terry Fry, Anne Chew, David G. Maloney, Carl H. June

Research output: Contribution to journalArticle

  • 10 Citations

Abstract

Exposure to replication-competent lentivirus (RCL) is a theoretical safety concern for individuals treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using methodology developed in the National Gene Vector Biorepository. All trials utilized third-generation lentiviral vectors produced by transient transfection. Samples from 26 clinical trials totaling 460 transduced cell products from 375 subjects were evaluated. All cell products were negative for RCL. A total of 296 of the clinical trial participants were screened for RCL at least 1 month after infusion of the cell product. No research subject has shown evidence of RCL infection. These findings provide further evidence attesting to the safety of third-generation lentiviral vectors and that testing T cell products for RCL does not provide added value to screening the lentiviral vector product. The safety of lentiviral vectors is a factor in their acceptance as clinical therapies. In this issue of Molecular Therapy, Cornetta et al. (2017) screened 460 cell products for replication-competent lentivirus (RCL); none were positive. The low risk of RCL suggests that revisions to U.S. FDA testing guidelines are warranted.

LanguageEnglish (US)
Pages280-288
Number of pages9
JournalMolecular Therapy
Volume26
Issue number1
DOIs
StatePublished - Jan 3 2018

Fingerprint

Lentivirus
T-Lymphocytes
Safety
Genetic Therapy
Lentivirus Infections
Clinical Trials
Research Subjects
Immunotherapy
Transfection
Guidelines
Therapeutics

Keywords

  • clinical gene therapy
  • immunotherapy
  • lentivirus
  • replication-competent virus
  • safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., ... June, C. H. (2018). Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. Molecular Therapy, 26(1), 280-288. https://doi.org/10.1016/j.ymthe.2017.09.008

Absence of Replication-Competent Lentivirus in the Clinic : Analysis of Infused T Cell Products. / Cornetta, Kenneth; Duffy, Lisa; Turtle, Cameron J.; Jensen, Michael; Forman, Stephen; Binder-Scholl, Gwendolyn; Fry, Terry; Chew, Anne; Maloney, David G.; June, Carl H.

In: Molecular Therapy, Vol. 26, No. 1, 03.01.2018, p. 280-288.

Research output: Contribution to journalArticle

Cornetta, K, Duffy, L, Turtle, CJ, Jensen, M, Forman, S, Binder-Scholl, G, Fry, T, Chew, A, Maloney, DG & June, CH 2018, 'Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products' Molecular Therapy, vol. 26, no. 1, pp. 280-288. https://doi.org/10.1016/j.ymthe.2017.09.008
Cornetta, Kenneth ; Duffy, Lisa ; Turtle, Cameron J. ; Jensen, Michael ; Forman, Stephen ; Binder-Scholl, Gwendolyn ; Fry, Terry ; Chew, Anne ; Maloney, David G. ; June, Carl H. / Absence of Replication-Competent Lentivirus in the Clinic : Analysis of Infused T Cell Products. In: Molecular Therapy. 2018 ; Vol. 26, No. 1. pp. 280-288.
@article{304fa2cb7cf04cd88fe19327f684c5de,
title = "Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products",
abstract = "Exposure to replication-competent lentivirus (RCL) is a theoretical safety concern for individuals treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using methodology developed in the National Gene Vector Biorepository. All trials utilized third-generation lentiviral vectors produced by transient transfection. Samples from 26 clinical trials totaling 460 transduced cell products from 375 subjects were evaluated. All cell products were negative for RCL. A total of 296 of the clinical trial participants were screened for RCL at least 1 month after infusion of the cell product. No research subject has shown evidence of RCL infection. These findings provide further evidence attesting to the safety of third-generation lentiviral vectors and that testing T cell products for RCL does not provide added value to screening the lentiviral vector product. The safety of lentiviral vectors is a factor in their acceptance as clinical therapies. In this issue of Molecular Therapy, Cornetta et al. (2017) screened 460 cell products for replication-competent lentivirus (RCL); none were positive. The low risk of RCL suggests that revisions to U.S. FDA testing guidelines are warranted.",
keywords = "clinical gene therapy, immunotherapy, lentivirus, replication-competent virus, safety",
author = "Kenneth Cornetta and Lisa Duffy and Turtle, {Cameron J.} and Michael Jensen and Stephen Forman and Gwendolyn Binder-Scholl and Terry Fry and Anne Chew and Maloney, {David G.} and June, {Carl H.}",
year = "2018",
month = "1",
day = "3",
doi = "10.1016/j.ymthe.2017.09.008",
language = "English (US)",
volume = "26",
pages = "280--288",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Absence of Replication-Competent Lentivirus in the Clinic

T2 - Molecular Therapy

AU - Cornetta, Kenneth

AU - Duffy, Lisa

AU - Turtle, Cameron J.

AU - Jensen, Michael

AU - Forman, Stephen

AU - Binder-Scholl, Gwendolyn

AU - Fry, Terry

AU - Chew, Anne

AU - Maloney, David G.

AU - June, Carl H.

PY - 2018/1/3

Y1 - 2018/1/3

N2 - Exposure to replication-competent lentivirus (RCL) is a theoretical safety concern for individuals treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using methodology developed in the National Gene Vector Biorepository. All trials utilized third-generation lentiviral vectors produced by transient transfection. Samples from 26 clinical trials totaling 460 transduced cell products from 375 subjects were evaluated. All cell products were negative for RCL. A total of 296 of the clinical trial participants were screened for RCL at least 1 month after infusion of the cell product. No research subject has shown evidence of RCL infection. These findings provide further evidence attesting to the safety of third-generation lentiviral vectors and that testing T cell products for RCL does not provide added value to screening the lentiviral vector product. The safety of lentiviral vectors is a factor in their acceptance as clinical therapies. In this issue of Molecular Therapy, Cornetta et al. (2017) screened 460 cell products for replication-competent lentivirus (RCL); none were positive. The low risk of RCL suggests that revisions to U.S. FDA testing guidelines are warranted.

AB - Exposure to replication-competent lentivirus (RCL) is a theoretical safety concern for individuals treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using methodology developed in the National Gene Vector Biorepository. All trials utilized third-generation lentiviral vectors produced by transient transfection. Samples from 26 clinical trials totaling 460 transduced cell products from 375 subjects were evaluated. All cell products were negative for RCL. A total of 296 of the clinical trial participants were screened for RCL at least 1 month after infusion of the cell product. No research subject has shown evidence of RCL infection. These findings provide further evidence attesting to the safety of third-generation lentiviral vectors and that testing T cell products for RCL does not provide added value to screening the lentiviral vector product. The safety of lentiviral vectors is a factor in their acceptance as clinical therapies. In this issue of Molecular Therapy, Cornetta et al. (2017) screened 460 cell products for replication-competent lentivirus (RCL); none were positive. The low risk of RCL suggests that revisions to U.S. FDA testing guidelines are warranted.

KW - clinical gene therapy

KW - immunotherapy

KW - lentivirus

KW - replication-competent virus

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85039964399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039964399&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2017.09.008

DO - 10.1016/j.ymthe.2017.09.008

M3 - Article

VL - 26

SP - 280

EP - 288

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -